- In October 2024, EyePoint Pharmaceuticals, Inc. announced positive 16-week interim data from its ongoing Phase 2 VERONA trial for DURAVYU, a sustained delivery therapy with vorolanib, a selective tyrosine kinase inhibitor, formulated in the bioerodible Durasert E™ for diabetic macular edema (DME) patients. This positive outcome strengthens the company’s position in the DME treatment market and advances the potential for DURAVYU as a key therapy
- In October 2024, Oculis Holding AG announced that David Eichenbaum, M.D. will present an update on the DIAMOND Phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulation, at Innovate Retina for diabetic macular edema (DME). This presentation will highlight the progress of OCS-01 and enhance the company's visibility in the DME market
- In September 2024, Merck and EyeBio announced the launch of the Phase 2b/3 BRUNELLO trial to evaluate Restoret (MK-3000, formerly EYE103) for treating diabetic macular edema (DME). This trial advances Restoret as a potential treatment, strengthening Merck's position in the DME market
- In July 2024, Genentech, a member of the Roche Group, announced two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for treating diabetic macular edema (DME) and diabetic retinopathy (DR). This data reinforces Susvimo® as a promising long-term treatment option, enhancing the company's position in the diabetic eye disease market
- In May 2024, Merck and Eyebiotech Limited announced a definitive agreement for Merck, through a subsidiary, to acquire EyeBio. This acquisition strengthens Merck’s eye care portfolio and enhances its capabilities in the treatment of ocular diseases
- In January 2024, EyePoint Pharmaceuticals, Inc. announced the dosing of the first patient in the Phase 2 VERONA trial of EYP-1901 for diabetic macular edema (DME). EYP-1901 is a sustained delivery therapy with vorolanib, a selective tyrosine kinase inhibitor, formulated in bioerodible Durasert E. This milestone positions the company to advance EYP-1901 as a potential treatment for DME, enhancing its pipeline and market potential.
